CD163 and neoplasm: We suggest that PD-L1 positive CD3 + /CD4 + , CD3 + /CD8 + and CD68 + /CD163 + hot tumour-immune phenotypes may present promising subgroups for immune checkpoint therapy in squamous bladder cancer.